Format

Send to

Choose Destination
Curr Opin Gastroenterol. 2019 Feb 21. doi: 10.1097/MOG.0000000000000528. [Epub ahead of print]

Current treatment options for nonalcoholic fatty liver disease.

Shetty A1,2, Syn WK3,4,5,2.

Author information

1
Department of Medicine, UCLA, Los Angeles.
2
Akshay Shetty and Wing-Kin Syn co-wrote the manuscript.
3
Section of Gastroenterology, Ralph H Johnson, VAMC.
4
Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, USA.
5
Department of Physiology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.

Abstract

PURPOSE OF REVIEW:

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in the United States and is strongly associated to the metabolic syndrome. In this review, we will discuss the evidence behind the current recommendations on lifestyle modifications and available treatment options for NAFLD.

RECENT FINDINGS:

The unrelenting rise in obesity and diabetes epidemic has led to a large healthcare burden from NAFLD and it is projected to continue to grow over the next two decades. Lifestyle modification that leads to weight loss is effective at treating NAFLD, but these modifications require a multidisciplinary approach for success in the real world. Multiple pharmacologic treatment options have been studied with promising results, but none have been approved for treatment in the United States. Clinical trials are on-going to study further pharmacologic treatment alternatives.

SUMMARY:

NAFLD is the most common chronic liver disease in United States, and an independent risk factor for mortality. Implementation of lifestyle modifications through a multidisciplinary approach and careful selection of patients for pharmacologic interventions will be essential for successful management of NAFLD.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center